Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 May;25(3):329-336.
doi: 10.1007/s40256-024-00713-w. Epub 2024 Dec 31.

Clinical Pharmacokinetics and Pharmacodynamics of Baxdrostat

Jessica Huston  1 , Dontia Orey  2 , Ashish Kumar  3 , Andrew Ashchi  2 , Andrea Ashchi  2 , Jason Berner  4 , Yazan Alkhouri  5 , David Sutton  6 , Wasim Deeb  7 , Mohannad Bisharat  5 , Rebecca F Goldfaden  8
Affiliations
Review

Clinical Pharmacokinetics and Pharmacodynamics of Baxdrostat

Jessica Huston et al. Am J Cardiovasc Drugs. 2025 May.

Abstract

Patients with hypertension are at an increased risk of cardiovascular disease and death. Resistant hypertension, or hypertension that is unsuccessfully treated with multiple antihypertensive medications, further exacerbates the complications and negative outcomes for patients. A new pathway, via aldosterone synthesis inhibition, is currently being studied as a method to reduce blood pressure values in patients who are currently taking other antihypertensive medications. This review presents and discusses the current pharmacokinetic, pharmacodynamic, and clinical and scientific evidence pertaining to baxdrostat, a novel aldosterone synthase inhibitor.

PubMed Disclaimer

Conflict of interest statement

Declarations. Funding: No external funding was used in the preparation of this manuscript. Conflict of Interest: J.H., D.O., A.K., Andrea.A., Andrew.A., J.B., Y.A., D.S., W.D., M.B., and R.F.G. declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript. Ethics Approval: Not applicable. Consent to Participate: Not applicable. Consent for Publication: Not applicable. Code Availability: Not applicable. Data Availability Statement: Data sharing are not applicable to this article as no datasets were generated. Authors’ Contributions: J.H. was involved in supervision, data curation, analysis, reviewing, editing, and writing; D.O. was involved in data curation, analysis, and writing; A.K. was involved in data curation, analysis, and writing; Andrea.A. was involved in data curation, writing, and analysis; Andrew.A. was involved in data curation, analysis, and writing; J.B. was involved in reviewing and editing; Y.A. was involved in reviewing and editing; D.S. was involved in reviewing and editing; W.D. was involved in reviewing and editing; M.B. was involved in reviewing and editing; R.F.G. was involved in the conceptualization, project administration, reviewing, and editing.

References

    1. Ostchega Y, Fryar CD, Nwankwo T, Nguyen DT. Hypertension prevalence among adults aged 18 and over: United States, 2017–2018. NCHS Data Brief. 2020;364:1–8.
    1. Danaei G, Ding EL, Mozaffarian D, et al. The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors [published correction appears in PLoS Med. 2011 Jan;8(1). https://doi.org/10.1371/annotation/0ef47acd-9dcc-4296-a897-872d182cde57 ]. PLoS Med. 2009;6(4):e1000058. https://doi.org/10.1371/journal.pmed.1000058
    1. Jacobs AK, Anderson JL, Halperin JL. The evolution and future of ACC/AHA clinical practice guidelines: a 30-year journey: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;64(13):1373–84. https://doi.org/10.1016/j.jacc.2014.06.001 . - DOI - PubMed
    1. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels—updated overview and meta-analyses of randomized trials. J Hypertens. 2016;34(4):613–22. https://doi.org/10.1097/HJH.0000000000000881 . - DOI - PubMed
    1. Wang C, Yuan Y, Zheng M, et al. Association of age of onset of hypertension with cardiovascular diseases and mortality. J Am Coll Cardiol. 2020;75(23):2921–30. https://doi.org/10.1016/j.jacc.2020.04.038 . - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources